Podcast appearances and mentions of robin carhart harris

In part one of my in-depth conversation with Dr. Robin Carhart-Harris, we explore the political and cultural forces shaping the resurgence of psychedelic therapy. We critique the dominant psychiatric paradigm, which has long reduced mental illness to purely neurochemical dysfunction (leading to the rise of SSRIs), ignoring the psychological, social, and spiritual roots of psychological suffering. Carhart-Harris highlights how this narrow framework has failed to address rising rates of depression, PTSD, and OCD. We also discuss the historical reluctance of institutions like the NIH to fund psychedelic research, despite mounting evidence of its therapeutic potential. Under the previous leadership, psychedelic science was sidelined—but with new NIH leadership and a shifting political climate, there is fresh hope for meaningful support. The conversation emphasizes the need for a more holistic, integrative approach to mental health—one that values inner healing, human agency, and the transformative power of psychedelic experiences.Chapters:00:00 Introduction to Psychedelic Therapy12:48 The Political Landscape of Psychedelics19:12 The Shift in Mental Health Paradigms36:55 Understanding the Unique Power of Psychedelics48:38 Interconnectedness of Psychology, Biology, and Ethics56:11 Integration After Psychedelic Experiences01:04:10 Critique of NIH and Funding Challenges01:26:20 Psychedelics: Beyond Pharmacological Solutions01:31:35 Expectations and Their Impact on Therapy01:37:23 Efficacy and Side Effects of Psychedelic TherapyPodcast sponsors:1) Trinergy Health offers a 6-month program for mind-body recovery and wellness. Based on the foundational framework of Diet/trauma/toxins. To schedule an intake appointment, go to https://psychiatry2.com/schedule/ or call 262-955-6601. Use code Rav10 to get 10% discount for holistic psychiatry program.2) Alcami Elements - a natural, adaptogenic herbal supplement to kickstart your day!https://www.alcamielements.com/Receive 10% OFF first order or 30% OFF subscription order using code: ILLUSION This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.illusionconsensus.com/subscribe

In this episode, Robin Carhart-Harris, PhD joins to elucidate the intersection of psychedelics and neuroplasticity. Dr. Carhart-Harris is the Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco. Robin founded the Centre for Psychedelic Research at Imperial College London in April 2019, was ranked among the top 31 medical scientists in 2020, and in 2021, was named in TIME magazine's ‘100 Next' – a list of 100 rising stars shaping the future. Dr. Carhart-Harris begins by discussing the impact of psychedelics on neuroplasticity and mental health. He explains neuroplasticity as the brain's ability to change, emphasizing its role in mood disorders and substance use and describes how stress atrophies the brain, leading to mental illness. Dr. Carhart-Harris differentiates between neuroplasticity and neurogenesis, noting that while neurogenesis is limited in adults, neuroplasticity can be influenced by psychedelics like ketamine, psilocybin, and MDMA. In closing, he also discusses the entropic brain hypothesis, suggesting that increased brain entropy leads to richer subjective experiences.    In this episode, you'll hear: The relationship between neuroplasticity and “canalization”  Why homeostatic neuroplasticity may promote mental wellbeing Differences between ketamine, MDMA, and serotonergic psychedelics in terms of neuroplasticity The details of the entropic brain hypothesis Psychedelics' effect on the default mode network The frontiers of research into psychedelics and neuroplasticity  Quotes: “So changeability is what plasticity is. And neuroplasticity—that's the ability of the brain to change. Okay, and how is neuroplasticity related to mood disorders like depression and anxiety or substance use disorder or something like that? Well, that's a great question cause we don't have it entirely nailed down. But one of the most reliable findings in biological psychiatry is that stress atrophies the brain.” [2:47] “The main thing with ketamine is that the window of increased plasticity is brief… That makes sense because that reflects how ketamine seems to work therapeutically—that it provides relief somewhat short-term, unless it is twinned with, say, psychotherapy or you do repeat administration and get someone out of the rut they were in.” [22:15] “We've seen in people with depression, brain networks can become quite segregated from each other—they are ordinarily, they're quite functionally separate and distinct—but that modularity might be a bit elevated in depression. But what we've seen with psilocybin therapy is that separateness between systems, that segregated quality of organization of brain networks, brain systems actually decreases after psilocybin therapy for depression. I'll put it another way: the brain looks more globally interconnected after psilocybin therapy for depression and the magnitude of that… correlates with improvements.” [39:19]   Links: Carhart-Harris Lab website Dr. Carhart-Harris on X Dr. Carhart-Harris' 2025 article: “Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models” Dr. Carhart-Harris' 2012 article: “Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin” Dr. Carhart-Harris' 2010 article with Karl Friston: “The default-mode, ego-functions and free-energy: a neurobiological account of Freudian ideas” Psychedelic Medicine Association Porangui

What's the architecture of a DMT experience, who are the entities that regularly interact and what's their message? How can DMT therapy facilitate positive mental health outcomes?In this episode we're going to learn about the bizarre types of experience that users of DMT have; DMT being the most powerful hallucinogenic molecule on the planet. So we'll be getting into the background of psychedelics for mental health; and the particularities of DMT, the active ingredient in Ahyuasca and the psychedelic that most often presents entities that interact meaningfully with the experiencer; we're going to discuss the different types of entities: from mythological creatures, to Gods and Demons, to machine elves and aliens, and the significance of these same characters appearing significantly often without an obvious primer; we'll also discuss the importance of mystical experience and teacher /guide experiences to positive mental health outcomes.Fortunately our guest was the head researcher on a 2022 paper that looked at exactly this topic, the medical doctor and sports scientist professor at the University of Toronto, Dr. David Wyndham Lawrence. He's published over 35 scientific papers across sports science and psychedelics for medical use.What we discussed:00:00 Intro05:20 Concussion, sports mental health & psychedelic therapy.08:10 Bringing in Robin Carhartt-Harris on the gaps in sports mental health treatment.12:06 Why psychedelics for those already in psychological difficulty?14:04 Serotonin receptor - neuro-protective mitochondria function.15:00 DMT is endogenous to the brain. 18:20 Medical institution meets shamanism.23:50 David's DMT phenomenology paper.30:10 The architecture of the DMT world.32:60 Mostly positive, interactive entity encounters.37:05 Occasionally negative encounters.38:40 Negative psychedelic experiences study - Jules Evans.40:05 How much “Primers” from pop culture influence experiences.44:00 Alien encounters in %16 of participants.45:30 Medical procedures by entities in 9% of participants.47:05 Mystical experiences in %70 of participants.49:00 Familiarity/ sense of home in the experiences.52:20 Default Mode Network is less active during altered states.48:35 Ego dissolution Vs mystical experience.01:00:00 5meoDMT Vs DMT.01:03:20 Wise teacher experience in 32% of participants.01:05:20 Death bed palliative doses to alleviate fear of death.01:09:50 ‘You're not ready for this experience' message.01:11:05 Theories of DMT experiences evaluated.01:12:20 ”All models are false but some are useful”, anonymous statistician.References: David Lawrence, “Phenomenology and content of inhaled DMT” David Wyndham Lawrence and Robin Carhart-Harris, “Sports Medicine, Mental Health & Well-Being, and Psychedelics” Benny Shanon,  “Antipodies of the Mind”Matthew W. Johnson - Johns HopkinsAndrew Gallimore - “Death by Astonishment”Jules Evans et al, “Extended difficulties following the use of psychedelic drugs”Similarities between DMT and Alien encounters paperDavid W. Lawrence, “DMT Occasioned Familiarity and the Sense of Familiarity Questionnaire”Roland Griffiths, “Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer”

A panel discussion with Jim Harris, Rachel Zoeller, DPT, David W. McMillan, Ph.D., and Manesh Girn, Ph.D. Recorded live at the Aspen Psychedelic Symposium In this riveting and deeply personal conversation, moderator Jim Harris is joined by three pioneers at the intersection of neuroscience, psychedelics, and disability: Dr. Rachel Zoeller (Doctor of Physical Therapy and spinal cord injury survivor), Dr. David McMillan (Assistant Professor of Neurological Surgery at the University of Miami), and Dr. Manesh Girn (neuroscientist and postdoctoral researcher with Robin Carhart-Harris at UCSF). Together, they explore how psychedelics may do far more than treat depression or catalyze mystical experiences—they may also support healing and regeneration in the nervous system. The discussion opens with an acknowledgment that our cultural understanding of psychedelics has mostly focused on their psychological and spiritual effects. But as these experts reveal, the somatic potential of psychedelics is vast and understudied. They delve into promising areas like central and peripheral neuroplasticity, the anti-inflammatory effects of psychedelics, and how these mechanisms might play a role in healing from spinal cord injuries or paralysis. Dr. Girn breaks down the science behind psilocybin's interaction with 5-HT2A serotonin receptors, not only in the brain but also in the spinal cord. These receptors, when activated, may increase neuronal excitability and even help restore lost signaling in damaged motor pathways. He suggests that psychedelics could reopen “critical periods” for neuroplasticity—windows of opportunity for the nervous system to rewire and heal. Rachel Zoeller shares her powerful lived experience as both a physical therapist and a spinal cord injury patient. Her story brings the science to life, particularly her observation that psychedelic experiences help her reconnect to parts of her body affected by paralysis. Psychedelics, she suggests, have allowed her to rebuild mind-body communication and foster compassion toward her own physical limitations. She also underscores the need for patients to cultivate body awareness, meditation, and breathwork as essential tools for safe and effective psychedelic use. Dr. McMillan, who leads outreach at the Miami Project to Cure Paralysis, provides a clinical and safety-oriented perspective. While optimistic about the potential, he urges caution—especially with individuals who have high-level spinal cord injuries and are vulnerable to serious complications like autonomic dysreflexia. He stresses that before we can bring these treatments into clinical settings, we must carefully assess physiological risk, develop precise pharmacological protocols, and prioritize patient safety. The panel also addresses cultural and spiritual interpretations of spasticity. Drawing on both shamanic and somatic perspectives, they propose that these involuntary muscle contractions could be reinterpreted not as dysfunction, but as potential portals for healing, integration, or neurological feedback. The idea that such spasms might help the brain remap muscle groups is discussed as a provocative and hopeful reframe. The conversation wraps with a call to action: to bring together indigenous wisdom, embodied knowledge, rigorous science, and community storytelling in order to chart a new frontier in psychedelic medicine—one that does not leave the disabled community behind. As McMillan puts it, "There's a lesson to psychedelia from paralysis.” It's a reminder that neuropharmacology must consider not just molecules and mechanisms, but people and possibilities. Whether you're a clinician, researcher, patient, or curious explorer, this panel is a moving and illuminating look at how psychedelics could transform not only minds—but bodies. Thanks to Aspen Public Radio, Aspen Psychedelic Resource Center, Healing Advocacy Fund and Aspen Psychedelic Symposium for allowing us to share this podcast. A full agenda from the symposium can be found here.

This is a replay of a preview episode from our sister podcast Brave New World. Could psychedelics be used to help tackle mental health issues like depression and addiction? Evgeny Lebedev speaks to Professor David Nutt, one the leading researchers in this controversial field. He also speaks to Buzzfeed journalist Lara Parker who used ketamine assisted therapy to treat clinical depression. To hear the whole interview, including additional interviews with pioneers Robin Carhart-Harris and Amanda Feilding, search 'Brave New World Evening Standard' on your podcast provider. Hosted on Acast. See acast.com/privacy for more information.

Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USBuy Grow kit: https://modernmushroomcultivation.com/

Dr. Robin Carhart-Harris is a leading neuroscientist and the founder of the Center for Psychedelic Research at Imperial College London, pioneering groundbreaking studies on the therapeutic potential of psychedelics for mental health. 15 Daily Steps to Lose Weight and Prevent Disease PDF: https://bit.ly/46XTn8f - Get my FREE eBook now! Subscribe to The Genius Life on YouTube! - http://youtube.com/maxlugavere Watch my new documentary Little Empty Boxes - http://littleemptyboxes.com This episode is proudly sponsored by: Momentous is a new supplement brand that holds its products to rigorous quality and purity standards set by the NFL and NBA. I use their creatine and protein regularly. Visit livemomentous.com/genius to get 20% off. AG1 is my favorite multivitamin. Enjoy a free 1 year supply of vitamin D and 5 free AG1 travel packs with your first purchase. All you have to do is visit drinkag1.com/GENIUS. Fatty15 provides C15:0, a naturally occurring fatty acid found in full-fat dairy that may support cellular health and longevity—get 15% off at http://fatty15.com/MAX with code MAX!

In this episode of The Psychedelic Podcast, Paul F. Austin speaks with Dr. Robin Carhart-Harris at the inaugural Eudaimonia summit in West Palm Beach. Find full show notes and links here: https://thethirdwave.co/podcast/episode-287/?ref=278 As the founder of the world's first Centre for Psychedelic Research at Imperial College London and now the Ralph Metzner Distinguished Professor at UCSF, Dr. Carhart-Harris shares his research on how psychedelics affect the brain's default mode network. He explains the key differences between psychedelic therapy and traditional psychiatric medications, discusses his current studies examining the role of set and setting, and explores the unique properties of 5-MeO-DMT. The conversation weaves between detailed neuroscience, the challenges of integrating psychedelics into healthcare, and personal reflections on his 20-year commitment to advancing psychedelic research. Prof Carhart-Harris holds the Ralph Metzner Distinguished Professorship in Neurology and Psychiatry at University of California, San Francisco (UCSF), where he founded the Carhart-Harris Lab in 2023. His groundbreaking research includes human neuroimaging studies with LSD, psilocybin, MDMA, and DMT, along with clinical trials of psilocybin therapy for various disorders. He founded the world's first Centre for Psychedelic Research at Imperial College London in 2019. Named in TIME magazine's '100 Next' in 2021 and Vox Magazine's 'Future 50' in 2023, his current research at UCSF focuses on understanding the mechanisms of psychedelics and psychedelic therapy. Highlights: Origins and evolution of psychedelic research in neuroscience The role of default mode network in consciousness How psychedelics differ from traditional SSRIs The relationship between serotonin discovery and LSD research  Challenges of integrating psychedelic therapy into healthcare  Current research projects at UCS The unique properties of 5-MeO-DMT Personal reflections on 20 years in psychedelic research  Episode Link: Website Episode Sponsor: The Practitioner Certification Program by Third Wave's Psychedelic Coaching Institute.

What's it like to trip in a MRI? That question would send most people running for the emergency exits, but not this week's guest Executive Coach, Author and Speaker, Amy Wong. Amy shares her experience as a participant in a cutting-edge psilocybin study led by renowned researcher Robin Carhart-Harris at UCSF's Neuroscape Neuroscience center.   Combining images and information from the MRI machine, an EEG cap, simultaneous feedback via a handheld device while in the MRI and detailed interview notes, the study aimed to capture real-time brain signatures alongside subjective experiences during psilocybin trips.   Follow along as Amy details each of her four distinct psylocibin journeys as the very first participant in this cutting-edge study. Her story is a testament to the potential of psychedelics in personal transformation and scientific exploration.   You can find more about Amy and her book at her website: AlwaysOnPurpose.com   Don't forget to download my Psychedelic Safety Guide Including What to Do When Things Go Wrong on our beautiful website: PsychedelicDivas.com Follow Us on Instagram Watch Us on YouTube

Welcome back to The Trip Report Podcast, a production of Beckley Waves.Today's conversation is with Shamil Chandaria, and as I alluded to in last week's newsletter introducing computational neuroscience—it is the longest and most technical conversation we've had to date.I have wanted to speak with Shamil since I watched his lecture at Oxford titled The Bayesian Brain and Meditation.Shamil is a former advisor to Google DeepMind, co-foudner and research fellow at Imperial College London Centre for Psychedelic Research and Oxford University's Centre for Eudaimonia and Human Flourishing, and a co-author with Robin Carhart-Harris and the Imperial team of the influential 2023 paper titled Canalization and Plasticity in Psychopathology, Importantly for this conversation, Shamil is also a longtime meditation practitioner, and his current work is dedicated to exploring contemplative practices, spiritual awakening, and psychedelics through the lens of computational neuroscience. At the heart of the conversation is the Free Energy Principle, a relatively new concept in cognitive neuroscience that conceives of the brain as a prediction machine constantly updating its internal models to minimize prediction errors. This framework along with the Bayesian Brain Hypothesis show how the brain optimally processes sensory data through inference, which has profound implications for how we perceive and experience the world.We discuss:* The brain as a prediction machine* The convergence of ancient wisdom and modern neuroscience.* Defining human flourishing beyond the absence of suffering to include meaning, love, joy, connection, and psychological resilience.* The role of body sensations, emotions, and somatic practices in psychotherapy and how they tie into the brain's predictive coding mechanisms.* Spiritual awakening, liberation and human flourishing through a neurocomputational lens* The potential for integrating free energy principle-based models into the field of psychiatry, improving therapeutic approaches and mental health care.* And much moreMy takeaway from this conversation is that we are, in fact, in the midst of a paradigm shift—one that bridges the fields of meditation, psychology, psychedelics, phenomenology, psychiatry, and even artificial intelligence. This new understanding, grounded in the free energy principle, offers a unified theory that links ancient wisdom with modern neuroscience, reshaping how we think about consciousness, well-being, and what it means to be sentient.And now, I bring you my conversation with Shamil Chandaria.I want to highlight our friends at the Tiny Blue Dot Foundation (TBD), who have just announced their latest Request for Proposals for scientific studies of the Perception Box.Tiny Blue Dot Foundation strives to help people understand that they live in their own unique Perception Box whose walls can be expanded to minimize suffering, increase acceptance of self and others, and view trauma and other challenges as opportunities for growth.TBD has allocated $9,000,000 to fund up to 10 rigorous research projects related to The Science of the Perception Box. TBD ran similar RFPs over the last two years and funded a total of 23 projects thus far. Information about these projects can be found here and here.Listen to the episode on Substack, Spotify, Google or Apple.Credits:* Hosted by Zach Haigney * Produced by Zach Haigney, Erin Greenhouse, and Katelin Jabbari* Find us at thetripreport.com* Follow us on Instagram, Twitter, LinkedIn and YouTubeTheme music by MANCHO Sounds, Mixed and Mastered by Rollin Weary This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thetripreport.com

Send us a Text Message.About the guest: Robin Carhart-Harris, PhD is a neuroscientist & psychopharmacologist. His lab at the University of California-San Francisco studies the effects of psychedelics and other drugs on the human brain, using neuroimaging and other approaches.Episode summary: Nick and Dr. Carhart-Harris discuss: psychedelics & the human brain; functional connectivity & entropy in brain patterns; the “entropic brain” hypothesis of psychedelic drug action; psychiatry & depression; psychology, Carl Jung & Sigmund Freud; the FDA's rejection of MDMA-assisted psychotherapy for PTSD; latest research on psychedelics; and more.Related episodes:Anesthesia, Placebo Effects, Consciousness, Subjectivity, MDMA, Ketamine, Opioids, Psychedelics | Boris Heifets | #163DMT, Serotonin, Inflammation, Psychedelics, and Past, Present & Future of Psychedelic Medicine | David & Charles Nichols | #137*This content is never meant to serve as medical advice.Support the Show.All episodes (audio & video), show notes, transcripts, and more at the M&M Substack Try Athletic Greens: Comprehensive & convenient daily nutrition. Free 1-year supply of vitamin D with purchase.Try SiPhox Health—Affordable, at-home bloodwork w/ a comprehensive set of key health marker. Use code TRIKOMES for a 10% discount.Try the Lumen device to optimize your metabolism for weight loss or athletic performance. Use code MIND for 10% off.Learn all the ways you can support my efforts

Dopo essere stata nostra ospite nella prima stagione, Agnese Codignola, giornalista e divulgatrice, è tornata a trovarci per raccontarci il suo punto di vista sulla fine del mondo. Sta arrivando la fine del mondo? Come sarà e quanto tempo ci rimane ancora? Lo scopriremo insieme in questo episodio. Agnese Codignola collabora con i principali gruppi editoriali italiani (RCS, Espresso-Repubblica, Il Sole 24 Ore, Focus-Mondadori e altri) occupandosi di salute, alimentazione, sostenibilità ambientale e scienza in generale. Tra i suoi libri ricordiamo “Il corpo anticancro. Come con l'immunoterapia si può vincere la lotta contro i tumori”, “LSD. Da Albert Hofmann a Steve Jobs, da Timothy Leary a Robin Carhart-Harris: storia di una sostanza stupefacente”, “Il destino del cibo. Così mangeremo per salvare il mondo” e "Sta arrivando la fine del mondo?" scritto insieme ad altri 14 autori.

Welcome back to The Trip Report Podcast, a production of Beckley Waves, a Psychedelic Venture Studio.Today, I am speaking with Manesh Girn, Ph.D, a prominent researcher and science communicator in the field of psychedelics and neuroscience. Manesh is a postdoctoral researcher at UCSF in Robin Carhart-Harris's lab. His fascinating background bridges psychology, philosophy, and neuroscience.Manesh's journey into the world of psychedelics began in his late teens through an interest in meditation and spirituality. A profound experience with psilocybin during his undergraduate years ignited his passion for exploring the therapeutic and cognitive potentials of psychedelics. His work has taken him from the University of British Columbia to McGill University, where he completed his PhD focusing on the default mode network and its role in human cognition and behavior.In this conversation, we discuss:* Manesh's introduction to psychedelics and how his early experiences shaped his academic and research career.* The intersection of meditation, psychedelics, and the default mode network* His extensive research on the default mode network and how psychedelics affect it.* The concept of neurophenomenology and its significance in linking subjective experiences with brain dynamics.* The ambitious projects at UCSF, including the most comprehensive psychedelic brain imaging study to date.* His involvement in a large-scale international psychedelic brain imaging data-sharing consortium.* The future of psychedelics in enhancing human potential and creativity, particularly through the work of the Center for MINDS.Manesh is passionate about leveraging psychedelics to help people not just recover from mental health issues but also to thrive and reach their fullest potential.And now, I bring you my conversation with Manesh Girn.Listen to the episode on Substack, Spotify, Google or Apple.Credits:* Hosted by Zach Haigney * Produced by Zach Haigney, Erin Greenhouse, and Katelin Jabbari* Find us at thetripreport.com* Follow us on Instagram, Twitter, LinkedIn and YouTubeTheme music by MANCHO Sounds, Mixed and Mastered by Rollin Weary This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thetripreport.com

Dr. Manesh Girn is a postdoctoral neuroscientist and popular science content creator specializing in the neuroscience of psychedelic drugs. He currently works at the University of California, San Francisco, alongside psychedelic research pioneer Dr. Robin Carhart-Harris, where he conducts research on the neural mechanisms underlying the psychedelic experience and psychedelic-assisted psychotherapy. In addition to his research, Manesh runs a popular digital platform on Instagram and YouTube called "The Psychedelic Scientist”, where he shares the latest findings in psychedelic science in a digestible and easy to understand way.  In this episode, we discuss: Manesh's journey from head to heart, from bypassing emotions to inhabiting them. Emotion centred, body-focused therapy (beating pillows with weapons.) How Manesh got his start in psychedelic research. How an early psychedelic experience opened Manesh up to different takes on reality. Finding the support to go beyond intellect. The various healing/transformational modalities of: breathwork men's groups psychedelics conscious relationship training How different psychedelics affect our brains differently. Neuroplasticity: how psychedelics can help change thought patterns. Psychedelics for those with with trauma and depression. The importance of support in psychedelic journeys Setting down a belief that life is intrinsically unsafe. Learning to recognize people and situations that are safe. Integrating psychedelic experiences for lasting change. The importance of intention before and after a psychedelic journey. Psychedelics as an aid to innovation. Psychedelics for people in positions of power. Manesh's Youtube Manesh's website Manesh's InstagramArka Brotherhood Men's CommunitySee omnystudio.com/listener for privacy information.

Welcome back to The Trip Report Podcast, a production of Beckley Waves, a Psychedelic Venture Studio.Today, I am speaking with Dr. Pedro Texeira, Ph.D a scientist studying health behavior change and health psychology at the University of Lisbon and founder of the psychedelic educational non-profit Safe Journey.About 18 months ago, I came across a paper authored by Pedro, Robin Carhart-Harris, and others titled Psychedelics and Health Behaviour Change about the potential role of psychedelics in promoting lifestyle changes that are conducive to overall health, and I knew that this would be an increasingly relevant area of research and practice.Part of my intrigue with psychedelics as therapeutic tools is the wide array of conditions and issues for which they may be helpful.At a time when the dominant prescriptive mode in healthcare is “a different pill for every ill,” it is intriguing to see an emerging treatment that has been used for centuries and for which people have organically found helpful for many different conditions from PTSD, to Depression, to Cluster Headaches.Furthermore, the idea that society's most pressing healthcare challenges—chronic diseases—are downstream of environment and lifestyle is an inconvenient truth. The reality is that we can't ignore the impact of nutrition, exercise, sleep, our social environment, and other non-medical lifestyle factors that can be difficult to change.So, can psychedelic-based approaches help people make positive changes? Develop greater agency? Feel less compulsion?These are the questions that Pedro and his team are researching.In this conversation, we discuss:* Pedro's research in nutritional science and health activity* The rise of environmental and lifestyle-based chronic diseases* The early years of the field of behavioral psychology* Self Determination Theory and the relationship between one's perceived competence and motivation for change* The underlying psychological mechanisms of action in self-perception and health behavior change* The potential power of combining established behavioral interventions with psychedelics* What we can learn about behavior change following psychedelic experiences in naturalistic settings* And the importance of psychedelic public education And now I bring you my conversation with Dr. Pedro Teixeira.Listen to the episode on Substack, Spotify, Google or Apple.Credits:* Hosted by Zach Haigney * Produced by Zach Haigney, Erin Greenhouse, and Katelin Jabbari* Find us at thetripreport.com* Follow us on Instagram, Twitter, LinkedIn and YouTubeTheme music by MANCHO Sounds, Mixed and Mastered by Rollin Weary This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thetripreport.com

Can neuroscience explain what happens to the brain on psychedelics? And even if we map the brain while it's tripping, does that tell us why these experiences can be so transformative?  We'll talk with some of the pioneers in psychedelic research — from Amanda Feilding's boundary-busting work to Robin Carhart-Harris' theory of the "entropic brain." Also, renowned neuroscientist Christof Koch goes down the rabbit hole on 5-MeO-DMT, also known as toad venom.   Original Air Date: July 15, 2023 Interviews In This Hour: Exploring consciousness on toad venom — The godmother of the European psychedelic revival — How therapeutic psilocybin could help heal long-buried trauma — Magic mushrooms and the 'entropic brain' Guests: Christof Koch, Amanda Feilding, David Nutt, Robin Carhart-Harris Never want to miss an episode? Subscribe to the podcast. Want to hear more from us, including extended interviews and favorites from the archive? Subscribe to our newsletter.

[video available on spotify] i've dabbled in the world of psychedelics a little bit. i've taken mushrooms a few times, but i really don't know a lot about psychedelics. however, it's becoming an increasingly more relevant topic as it's been revealed that they can help with mental health issues and have therapeutic qualities. robin carhart-harris is a pioneer and leading researcher in neuroscience and psychopharmacology, best known for his groundbreaking work on how psychedelics affect the brain and how they can be used to treat mental health issues. in 2019, he founded the world's first center for psychedelic research at imperial college london. basically, he's all about using psychedelics to help human suffering to improve the quality of people's lives. so today, we're going to learn a new definition of psychedelics with robin carhart-harris. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In recent years there's been a renaissance of interest in psychedelics in the West, on a scale not seen since the first wave of medical research in the 1950s and 60s. Drugs like DMT, ketamine and psilocybin (the psychoactive compound in magic mushrooms), are now being researched as medications to take alongside therapy for the treatment of various mental health problems. Across this series of interviews, Rose Cartwright explores so-called ‘psychedelic assisted psychotherapy'. What is it? Can it help tackle our mental health crisis? And what are the risks?Her guest today is Dr Robin Carhart-Harris, one of the world's leading psychedelics researchers, former founder of the Centre for Psychedelic Research at Imperial College London, and now Professor of Neurology, Psychiatry and Behavioural Sciences at the University of California. How to these drugs work on the brain? What are the current medical trials indicating? And how are the laws around the medical use of these drugs changing? Producer: Becky Ripley

Today's episode explores the potential of psychedelics in various aspects of mental and physical health, from treating depression to confronting death anxiety. Deepak Chopra shares some personal stories about his experiences in the areas of consciousness exploration and psychedelics, while Dr. Robin Carhart-Harris shares scientific findings which give hope to the revolution of our current healthcare system.

In this episode, Joe interviews Dr. Robin Carhart-Harris: founder and head of the Centre for Psychedelic Research at Imperial College London, founding director of the Neuroscape Psychedelics Division at University of California, San Francisco (UCSF), and founder of the Carhart-Harris Lab. A legendary researcher, he talks about his psychedelic origins: studying Freud, Jung, and eventually Stan Grof and depth psychology to try and better understand the unconscious. He discusses the growth of psychedelics and the cultural shifts he's noticed (especially in the U.S.), as well as what he's working on today: researching the influence of psychedelics on set and setting by studying experiences in both enriched and unenriched environments. He also talks about: Plasticity: how he defines it, how it relates to critical reopening periods, and how it's a fundamental thing that transcends the metrics we use to measure it Early LSD studies, the nervousness surrounding he and David Nutt dosing Ben Sessa, and the youthful energy that kept them going How plasticity could be exploited to help relieve chronic pain The potential of psychedelics to help with fibromyalgia and anorexia How psychedelic-assisted therapy brought care back to health care and more! UCSF is seeking survey volunteers, so if you've had more than three experiences with ketamine, MDMA, and psilocybin (must have experiences with all three) and want to contribute, do so here. Click here to head to the show notes page. 

A conversation about psychedelics with holistic facilitator Steve Elfrink of Om Terra Psychedelics. How dreams and psychedelics shift consciousness and help resolve trauma. He describes primary consciousness as the body and the subconscious while secondary consciousness is everyday awareness. Primary consciousness is present all the time, but is deeply accessed through dreaming and psychedelics. Steve recommends what he calls a psycholytic dose to help get out of a loop of unresolved emotions, but he cautions that a psychedelic session is just the beginning of a healing journey. In the second half, Steve shares his own riveting journey with psychedelics and Max asks where one can find psychedelic assistance. Resources mentioned during the show include Robin Carhart-Harris, Peter Levine, Bessel van der Kolk, Third Wave, Psychable. Today marks the fifth anniversary of the Dream Journal! Check us out on IG and FB @ExperientialDreamwork and follow #TheDreamJournal BIO: Steve Elfrink is the founder of OmTerra, a psychedelic therapy organization. He is also Co-Founder of The Rogue Valley Psychedelic Society, and the Subject Matter Expert for Webdelics, an online resource for psychedelics. He is a fresh voice to the more harrowing and less discussed challenges that come with psychedelic therapy. Find our guest at: OmTerra.org Episode number 246 recorded during a live broadcast on February 17, 2024 at KSQD.org, community radio of Santa Cruz. Intro and outro music by Mood Science. Ambient music new every week by Rick Kleffel. Archived music can be found at Pandemiad.com. Many thanks to Rick Kleffel for also engineering the show and to Tony Russomano for the phones. SHARE A DREAM FOR THE SHOW or a question by emailing Katherine Bell at katherine@ksqd.org. Follow on FB and IG @ExperientialDreamwork #thedreamjournal. To learn more or to inquire about exploring your own dreams go to ExperientialDreamwork.com. The Dream Journal is produced at and airs on KSQD Santa Cruz, 90.7 FM. Catch it streaming LIVE at KSQD.org 10-11am Pacific Time on Saturdays. Call or text with your dreams or questions at 831-900-5773 or email at onair@ksqd.org. Podcasts are available on all major podcast platforms released the Monday following the live show. The complete KSQD Dream Journal podcast page can be found at ksqd.org/the-dream-journal/. Now also available on PRX at Exchange.prx.org/series/45206-the-dream-journal Thanks for being a Dream Journal listener! Available on all major podcast platforms. Rate it, review it, subscribe and tell your friends.

Could psychedelics be used to help tackle mental health issues like depression and addiction? In this preview episode of Brave New World, Evgeny Lebedev speaks to Professor David Nutt, one the leading researchers in this controversial field. He also speaks to Buzzfeed journalist Lara Parker who used ketamine assisted therapy to treat clinical depression.To hear the whole interview, including additional interviews with pioneers Robin Carhart-Harris and Amanda Feilding, search 'Brave New World Evening Standard' on your podcast provider. Hosted on Acast. See acast.com/privacy for more information.

Could psychedelics be used to help tackle mental health issues like depression and addiction? In this preview episode of Brave New World, Evgeny Lebedev speaks to Professor David Nutt, one the leading researchers in this controversial field. He also speaks to Buzzfeed journalist Lara Parker who used ketamine assisted therapy to treat clinical depression. To hear the whole interview, including additional interviews with pioneers Robin Carhart-Harris and Amanda Feilding, search 'Brave New World Evening Standard' on your podcast provider. Hosted on Acast. See acast.com/privacy for more information.

Could psychedelics be used to help tackle mental health issues like depression and addiction? In this episode of Brave New World, Evgeny Lebedev speaks to Professor David Nutt, one the leading researchers in this controversial field. His former student, now professor, Robin Carhart-Harris, describes the impact of his study comparing psychedelic medicine with mainstream medicine. Evgeny also meets pioneers like Amanda Feilding who developed the first images of the brain on LSD, and the psychologist Bill Richards who explains his research into consciousness. He also speaks to Buzzfeed journalist Lara Parker who used ketamine assisted therapy to treat clinical depression. In this episode:How do psychedelics really affect the brain?Why David Nutt says they can “disrupt the thought loops” behind depressionHow effective is ketamine assisted therapy?Robin Carhart-Harris describes his work with ‘magic mushrooms'Why Amanda Feilding set up the Foundation to Further ConsciousnessBill Richardson on why ‘mystical consciousness' is becoming “a scientific term”If you enjoyed this episode, please leave us a review and hit the follow button on your podcast provider so you never miss an episode of Brave New World. Hosted on Acast. See acast.com/privacy for more information.

Dr. Robin Carhart-Harris is a distinguished professor of neurology and psychiatry at the University of California, San Francisco, and one of the foremost experts on the interplay of neuroscience and psychedelics. He studies how psychedelics such as psilocybin, LSD and DMT can change the human brain and be used to treat various mental health challenges such as trauma disorders, major depression, obsessive-compulsive disorder (OCD), and addiction. Dr. Carhart-Harris joined Rep. Crenshaw to discuss the latest findings from clinical trials of psychedelic therapies, how the mind is affected by the different kinds of psychedelics, the legal landscape for these therapies, and the risks and benefits he sees in psychedelics, other prescription drugs, and alcohol. Follow Dr. Carhart-Harris on X at @RCarhartHarris.

Joe and Rolf talk to psychedelic researcher Robin Carhart-Harris. Robin is at the cutting edge of research on the therapeutic benefits of psychedelics such as psilocybin (magic mushrooms), LSD, and DMT. He discusses psychotherapy and the unconscious mind, models of what psychedelics are doing in the brain, and many other topics. A really fascinating and in-depth conversation. You can find links to his published research as well as a series of videos on harm reduction at the following link: https://www.carhartharrislab.com/ Special Guest: Robin Carhart-Harris.

Siyamak sits down with Professor Robin Carhart-Harris from the University of California San Francisco (UCSF) to explore decriminalizing psychedelic drugs in California. "With this massive scaling up, can we ensure the kind of safety and efficacy that we've seen in these small trials? It's a really valid question." ⭕️Watch in-depth videos based on Truth & Tradition at Epoch TV

Sam Harris speaks with Jeannie Fontana and Robin Carhart-Harris about the TREAT Initiative in California and the growing promise of psychedelics for mental health care. If the Making Sense podcast logo in your player is BLACK, you can SUBSCRIBE to gain access to all full-length episodes at samharris.org/subscribe. Learning how to train your mind is the single greatest investment you can make in life. That's why Sam Harris created the Waking Up app. From rational mindfulness practice to lessons on some of life's most important topics, join Sam as he demystifies the practice of meditation and explores the theory behind it.

Share this episode: https://www.samharris.org/podcasts/making-sense-episodes/337-the-future-of-psychedelic-medicine Sam Harris speaks with Jeannie Fontana and Robin Carhart-Harris about the TREAT Initiative in California and the growing promise of psychedelics for mental health care. Jeannie Fontana, MD, PhD, is a multifaceted leader in healthcare, specializing in Internal Medicine, Environmental Toxicology, and Biochemistry and Molecular Biophysics. She initiated an ALS-focused research team at Sanford Burnham Prebys and established the Cedars-Sinai ALS Center of Excellence, driving policy change and boosting federal funding for ALS research. As a founding trustee of the California Institute for Regenerative Medicine (CIRM), she played a pivotal role in creating the world's largest stem cell granting agency with an $8.5 billion budget. Under her influence, the agency has achieved FDA approvals, fast-track designations, and launched groundbreaking clinical trials. Additionally, CIRM catalyzed the creation of over 55,000 jobs, 50 new companies, and $10 billion in added state revenue. Now, Jeannie is poised to address California's urgent mental health crisis through her role in the TREAT California Initiative. Website: treatcalifornia.org Robin Carhart-Harris, PhD, moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol. He has designed human brain imaging studies with LSD, psilocybin, MDMA and DMT, and several clinical trials of psilocybin therapy for severe mental illnesses, including 3 key trials in depression plus 2 further trials in anorexia and fibromyalgia syndrome. Dr Carhart-Harris founded the Centre for Psychedelic Research at Imperial College London in April 2019, the first of its kind in the world. In 2020, he was named among the top 31 medical scientists by The Times newspaper. Dr Carhart-Harris became the inaugural Ralph Metzner Distinguished Professor of Neurology and Psychiatry at the University of California San Francisco in 2021, and in the same year, was listed in TIME magazine’s ‘100 Next’ - a list of emerging leaders from around the world who are shaping the future. Website: carhartharrislab.com Twitter: @RCarhartHarris Learning how to train your mind is the single greatest investment you can make in life. That’s why Sam Harris created the Waking Up app. From rational mindfulness practice to lessons on some of life’s most important topics, join Sam as he demystifies the practice of meditation and explores the theory behind it.

Hello and welcome to Entangled! The podcast where we explore the science of consciousness, the true nature of reality, and what it means to be a spiritual being having a human experience. I'm your host Jordan Youkilis, and today I'm joined by Dr. Fred Travis as part of the miniseries on Maharishi Vedic Science. Dr. Travis is Chair of the Department of Maharishi Vedic Science at Maharishi International University, Dean of the Graduate School, and Director of the Center for Brain, Consciousness, & Cognition. In this episode, Dr. Travis describes the points of contention regarding the nature of consciousness between Vedic science and Western science, including the explanatory gap. We next discuss the states of consciousness and the different physiological characteristics of each. From there, Dr. Travis explains the different types of intelligence, the different types of meditation, and how to know if you've experienced Transcendental Consciousness. We then dive into the ongoing paradigmatic revolution from materialist to consciousness-based cosmology. We next consider whether consciousness is non-localized and how medicine will change when we switch to a consciousness-based paradigm. From there, we discuss TM vs. psychedelics and the phenomenon of unconstrained cognition. We end the conversation discussing the collective consciousness, field effects of consciousness, and their implications for the viability of World Peace. Outros available for this and all episodes available at entangledpodcast.substack.com. Music from the show available on the Spotify playlist “Entangled – The Vibes”. Please enjoy!Music: Intro: Ben Fox - "The Vibe". End music: Family Kush – “Brain Zap”.Recorded: 01/26/23. Published: 07/31/23.Outro: "Neuroscience & Consciousness: Explaining the Explanatory Gap" (starts at 1:05:57).Check out the resources mentioned:* Dr. Travis's Website: http://drfredtravis.com/* Maharishi International University: https://www.miu.edu/* Center for Brain, Consciousness & Cognition: https://research.miu.edu/center-for-brain-consciousness-and-cognition/* Your Brain is a River not a Rock by Dr. Fred Travis: https://www.amazon.com/Your-Brain-River-Not-Rock/dp/1469937212* One Unbounded Ocean of Consciousness by Dr. Tony Nader: https://www.amazon.com/One-Unbounded-Ocean-Consciousness-Questions/dp/B09NP8VL8W* “Testing the field Paradigm of Maharishi's Vedic psychology” by Dr. Fred Travis: https://www.proquest.com/openview/f2583c79fb0354344491673df482f33a/1?pq-origsite=gscholar&cbl=18750&diss=y* “Idealism, Panpsychism, Oneness and Multiplicity” with Dr. Tony Nader and Dr. Philip Goff: * “Relation between Psychedelic and Transcendental Experiences” by Dr. Fred Travis: https://ccsenet.org/journal/index.php/ijps/article/view/0/47981* “Psychedelics, Meditation, and Self-Consciousness” by Raphael Milliere, Robin Carhart-Harris, et. al.: This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit entangledpodcast.substack.com

On this week's episode, WHOOP VP of Performance Science, Principal Scientist, Kristen Holmes is joined by Dr. Robin Carhart-Harris, a distinguished professor of neurology and psychiatry at the University of California, San Francisco. He is one of the leading researchers in the study of how psychedelics such as psilocybin, LSD, and DMT can change the human brain and in doing so, be used to successfully treat various mental health challenges such as major depression, anorexia, obsessive-compulsive disorder (OCD) and addiction. Kristen and Robin discuss the etymology of psychedelics (2:30), researching altered states and altered consciousness (6:35), recreational use of psychedelics (12:53), how attitudes around psychedelics are changing (16:00), the most promising and exciting aspects of psychedelic research (19:11), physiological markers impacted by psychedelics (24:20), the optimal time to explore psychedelic treatment (31:00), what it means to biologically “let go” (35:35), the performance-enhancing possibilities of psychedelics (39:57), legality in the U.S. (45:11), what Robin is obsessing over (50:20), and the biggest benefits of psychedelics (51:35).Resources:Psychedelics and the Impact on Veterans and PTSDDr. Carhart-Harris on TwitterSupport the show

Can neuroscience explain what happens to the brain on psychedelics? And even if we map the brain while it's tripping, does that tell us why these experiences can be so transformative?  We'll talk with some of the pioneers in psychedelic research — from Amanda Feilding's boundary-busting work to Robin Carhart-Harris' theory of the "entropic brain." Also, renowned neuroscientist Christof Koch goes down the rabbit hole on 5-MeO-DMT, also known as toad venom.   Original Air Date: July 15, 2023 Interviews In This Hour: Exploring consciousness on toad venom — The godmother of the European psychedelic revival — How therapeutic psilocybin could help heal long-buried trauma — Magic mushrooms and the 'entropic brain' Guests: Christof Koch, Amanda Feilding, David Nutt, Robin Carhart-Harris Never want to miss an episode? Subscribe to the podcast. Want to hear more from us, including extended interviews and favorites from the archive? Subscribe to our newsletter.

Can neuroscience explain what happens to the brain on psychedelics? And even if we map the brain while it's tripping, does that tell us why these experiences can be so transformative?  We'll talk with some of the pioneers in psychedelic research — from Amanda Feilding's boundary-busting work to Robin Carhart-Harris' theory of the "entropic brain." Also, renowned neuroscientist Christof Koch goes down the rabbit hole on 5-MeO-DMT, also known as toad venom.   Original Air Date: July 15, 2023 Interviews In This Hour: Exploring consciousness on toad venom — The godmother of the European psychedelic revival — How therapeutic psilocybin could help heal long-buried trauma — Magic mushrooms and the 'entropic brain' Guests: Christof Koch, Amanda Feilding, David Nutt, Robin Carhart-Harris Never want to miss an episode? Subscribe to the podcast. Want to hear more from us, including extended interviews and favorites from the archive? Subscribe to our newsletter.

You know all the stuff we've been talking about here the past few years - mental mountains, trapped priors, relaxed beliefs under psychedelics? The new keyword for all of that is “canalization”. At least that's what I gather from a giant paper recently published by some of the leading thinkers in computational psychiatry (Karl Friston, Robin Carhart-Harris, etc). A quick review: you can model the brain as an energy landscape . . . . . . with various peaks and valleys in some multidimensional space Situations and stimuli plant “you” at some point on the landscape, and then you “roll down” towards some local minimum. If you're the sort of person who repeats “I hate myself, I hate myself” in a lot of different situations, then you can think of the action of saying “I hate myself” as an attractor - a particularly steep, deep valley which it's easy to fall into and hard to get out of. Many situations are close to the slopes of the “I hate myself” valley, so it's easy to roll down and get caught there. What are examples of valleys other than saying “I hate myself”? The authors suggest habits. If you always make the sign of the cross when passing a graveyard, there's a steep slope from the situation of passing a graveyard to the action of signing the cross. We can be even broader: something really basic like edge-detection in the visual system is a valley. When you see a scene, you almost always want to automatically do edge-detection on it. Walking normally is a valley; there's a certain correct sequence of muscle movements, and you don't want to start rotating your ligaments in some weird direction halfway through. https://astralcodexten.substack.com/p/the-canal-papers tt

Psychedelic scientist Manesh Girn joins Paul F. Austin to reveal the impact of psychedelics on the brain as a whole. Find episode links, summary, and transcript here. Manesh Girn is in the latter stages of obtaining his Ph.D. in Neuroscience at McGill University and has been the lead or co-author on over a dozen scientific publications and book chapters on topics including psychedelics and the default mode network.  He is currently researching the brain mechanisms underlying psychedelic drugs in collaboration with Dr. Robin Carhart-Harris and other leaders in psychedelic science. As a postdoctoral psychedelic neuroscientist, he will join Dr. Carhart-Harris at UCSF in August 2023. Manesh is also Chief Research Officer at the Canadian psychedelic bioscience company EntheoTech Bioscience. He runs a YouTube channel and Instagram page called The Psychedelic Scientist, where he discusses the latest research in an easy-to-understand but non-superficial form. Girn advocates for a personalized approach to psychedelic research that considers individual brain characteristics, mental health conditions, and environment in order to truly understand their effects. He challenges the misconception that psychedelics are inherently beneficial and highlights the importance of positive inputs for positive outcomes. This compelling conversation further explores the influence of set and setting, the interdisciplinary nature of psychedelics, and their potential to shape self-identity. Manesh and Paul F. Austin uncover profound insights into the neuroscience of psychedelics and the need for personalized, comprehensive research. Episode Sponsors: CURED Nutrition's Serenity Gummies. Get 15% off by using coupon code “THIRDWAVE” at checkout.  Sayulita Wellness Retreats Third Wave's Mushroom Grow Kit - use code 3WPODCAST to save $75.  

Huberman Lab Key Takeaways “Psychedelics seem to give people access to a better version of self.” – Dr. Andrew HubermanPossibly in part because of ego dissolution properties of psychedelics (versus ego inflation properties of drugs like cocaine)Psychedelics can reveal something about the mind that can't be revealed otherwise – maybe because it's masked, unconscious, or below the threshold of awarenessPsilocybin changes the brain in a way that allows new ideas and new forms of learning to occurMore classic psychedelics like psilocybin allow you to dive deeper into the uncomfortable in a way that MDMA does not MDMA is a strong empathogen for self and othersThe setting plays a huge role in the outcomes of psychedelic studies; features include: strategic music, eye mask, 2 non-using professionals + 1 client/patient, 1-3 sessions spread across a few weeks, integration with psychotherapy (talk therapy)Despite the massive attention it's gotten, the evidence doesn't currently support any benefits of microdosing – just macrodosing under clinical supervisionThe psychedelic renaissance has come a long way! From fringe science and taboo culture to a huge draw for donors and openly discussed and researched in academic settingsRead the full notes @ podcastnotes.orgIn this episode, my guest is Robin Carhart-Harris, PhD, distinguished professor of neurology and psychiatry at the University of California, San Francisco. He is one of leading researchers in the study of how psychedelics such as psilocybin, LSD and DMT can change the human brain and in doing so, be used to successfully treat various mental health challenges such as major depression, anorexia, obsessive-compulsive disorder (OCD) and addiction. He explains how psilocybin induces sustained changes in adaptive brain wiring and cognition. We discuss the key components of safe and effective psychedelic journeys, the role of hallucinations, the use of eye-masks to encourage people to “go internal,” and music, as well as what effective therapist support consists of before, during and after the session (also known as integration). We discuss micodosing vs. macrodosing and how researchers control for placebo effects in psychedelic research. We also discuss the current legal landscape around psychedelic therapies. Psychedelic therapies are fast emerging as powerful and soon-to-be mainstream treatments for medical health disorders, but they are not without their risks. As such, this episode ought to be of use to anyone interested in brain plasticity, mental health, psychology or neuroscience. For the full show notes, visit hubermanlab.com. Thank you to our sponsors AG1 (Athletic Greens): https://athleticgreens.com/huberman Eight Sleep: https://eightsleep.com/huberman Levels: https://levels.link/huberman HVMN: https://hvmn.com/huberman LMNT: https://drinklmnt.com/huberman Momentous: https://www.livemomentous.com/huberman The Brain Body Contract https://hubermanlab.com/tour Timestamps (00:00:00) Dr. Robin Carhart-Harris (00:02:12) Sponsors: Eight Sleep, Levels, HVMN (00:05:41) The Brain-Body Contract (00:06:31) Origin of the Word: “Psychedelics”; Pharmacology (00:12:05) Psychedelics & Revealing the Unconscious Mind, Psychotherapy (00:17:32) Microdosing (00:26:08) Psilocybin vs. Magic Mushroom Doses (00:28:28) “Psychedelic-Therapy”, Music (00:35:12) Sponsor: AG1 (Athletic Greens) (00:36:26) Psychedelic Journey: “Trust, Let Go, Be Open” (00:43:01) Negative Emotions, Fear & Psychedelics (00:46:21) Global Functional Connectivity, Serotonin 2A Receptor; Subjective Experiences (00:52:33) Pharmacology: Therapeutics without Psychedelic Effects; SSRIs (00:58:45) Psilocybin & Depression; Long-Term Effects: Connectivity & Neuroplasticity (01:09:14) Sponsor: LMNT (01:10:26) Psilocybin Therapy & Anorexia (01:12:56) Integration Phase & Psychedelic-Therapy; Meditation (01:19:50) First-Time Psychedelic Use, “Entropic Brain Effect”, Neuroplasticity, Cognition (01:30:16) Fibromyalgia & Psychedelic Treatment; MDMA Therapy & “Inner Healer” (01:38:55) Placebo Response & Psychedelic Therapy (01:41:39) LSD & Psychedelic-Therapy, Micro-Dose (01:48:19) Combination Psilocybin-MDMA Therapy (01:56:06) DMT “Rocketship” & Serotonin 2A Receptors; Ibogaine (02:01:04) “Ego Dissolution”, Cocaine vs. Psychedelics; Relapses (02:12:26) Psychedelics & Legal Landscape; Decriminalization (02:17:54) MDMA, Trauma & Clinical Trials; Future Regulatory (FDA) Approval? (02:23:25) Psilocybin & Current Clinical Trials (02:28:41) Mental Health & Psychedelic Treatment, Safeguards, Paradigm Shift (02:34:39) Zero-Cost Support, YouTube Feedback, Spotify & Apple Reviews, Sponsors, Momentous, Social Media, Neural Network Newsletter Title Card Photo Credit: Mike Blabac Disclaimer

In this episode, my guest is Robin Carhart-Harris, PhD, distinguished professor of neurology and psychiatry at the University of California, San Francisco. He is one of leading researchers in the study of how psychedelics such as psilocybin, LSD and DMT can change the human brain and in doing so, be used to successfully treat various mental health challenges such as major depression, anorexia, obsessive-compulsive disorder (OCD) and addiction. He explains how psilocybin induces sustained changes in adaptive brain wiring and cognition. We discuss the key components of safe and effective psychedelic journeys, the role of hallucinations, the use of eye-masks to encourage people to “go internal,” and music, as well as what effective therapist support consists of before, during and after the session (also known as integration). We discuss micodosing vs. macrodosing and how researchers control for placebo effects in psychedelic research. We also discuss the current legal landscape around psychedelic therapies. Psychedelic therapies are fast emerging as powerful and soon-to-be mainstream treatments for medical health disorders, but they are not without their risks. As such, this episode ought to be of use to anyone interested in brain plasticity, mental health, psychology or neuroscience. For the full show notes, visit hubermanlab.com. Thank you to our sponsors AG1 (Athletic Greens): https://athleticgreens.com/huberman Eight Sleep: https://eightsleep.com/huberman Levels: https://levels.link/huberman HVMN: https://hvmn.com/huberman LMNT: https://drinklmnt.com/huberman Momentous: https://www.livemomentous.com/huberman The Brain Body Contract https://hubermanlab.com/tour Timestamps (00:00:00) Dr. Robin Carhart-Harris (00:02:12) Sponsors: Eight Sleep, Levels, HVMN (00:05:41) The Brain-Body Contract (00:06:31) Origin of the Word: “Psychedelics”; Pharmacology (00:12:05) Psychedelics & Revealing the Unconscious Mind, Psychotherapy (00:17:32) Microdosing (00:26:08) Psilocybin vs. Magic Mushroom Doses (00:28:28) “Psychedelic-Therapy”, Music (00:35:12) Sponsor: AG1 (Athletic Greens) (00:36:26) Psychedelic Journey: “Trust, Let Go, Be Open” (00:43:01) Negative Emotions, Fear & Psychedelics (00:46:21) Global Functional Connectivity, Serotonin 2A Receptor; Subjective Experiences (00:52:33) Pharmacology: Therapeutics without Psychedelic Effects; SSRIs (00:58:45) Psilocybin & Depression; Long-Term Effects: Connectivity & Neuroplasticity (01:09:14) Sponsor: LMNT (01:10:26) Psilocybin Therapy & Anorexia (01:12:56) Integration Phase & Psychedelic-Therapy; Meditation (01:19:50) First-Time Psychedelic Use, “Entropic Brain Effect”, Neuroplasticity, Cognition (01:30:16) Fibromyalgia & Psychedelic Treatment; MDMA Therapy & “Inner Healer” (01:38:55) Placebo Response & Psychedelic Therapy (01:41:39) LSD & Psychedelic-Therapy, Micro-Dose (01:48:19) Combination Psilocybin-MDMA Therapy (01:56:06) DMT “Rocketship” & Serotonin 2A Receptors; Ibogaine (02:01:04) “Ego Dissolution”, Cocaine vs. Psychedelics; Relapses (02:12:26) Psychedelics & Legal Landscape; Decriminalization (02:17:54) MDMA, Trauma & Clinical Trials; Future Regulatory (FDA) Approval? (02:23:25) Psilocybin & Current Clinical Trials (02:28:41) Mental Health & Psychedelic Treatment, Safeguards, Paradigm Shift (02:34:39) Zero-Cost Support, YouTube Feedback, Spotify & Apple Reviews, Sponsors, Momentous, Social Media, Neural Network Newsletter Title Card Photo Credit: Mike Blabac Disclaimer

​ @JordanBPeterson  in his conversation with Robin Carhart-Harris nails how prayer works psychologically without even saying the word prayer. https://youtu.be/4NtKdisg0GA    Paul Vander Klay clips channel https://www.youtube.com/channel/UCX0jIcadtoxELSwehCh5QTg Bridges of Meaning Discord https://discord.gg/EKTbZHWF https://www.meetup.com/sacramento-estuary/ My Substack https://paulvanderklay.substack.com/ Estuary Hub Link https://www.estuaryhub.com/ If you want to schedule a one-on-one conversation check here. https://paulvanderklay.me/2019/08/06/converzations-with-pvk/ There is a video version of this podcast on YouTube at http://www.youtube.com/paulvanderklay To listen to this on ITunes https://itunes.apple.com/us/podcast/paul-vanderklays-podcast/id1394314333  If you need the RSS feed for your podcast player https://paulvanderklay.podbean.com/feed/  All Amazon links here are part of the Amazon Affiliate Program. Amazon pays me a small commission at no additional cost to you if you buy through one of the product links here. This is is one (free to you) way to support my videos.  https://paypal.me/paulvanderklay To support this channel/podcast with Bitcoin (BTC): 37TSN79RXewX8Js7CDMDRzvgMrFftutbPo  To support this channel/podcast with Bitcoin Cash (BCH) qr3amdmj3n2u83eqefsdft9vatnj9na0dqlzhnx80h  To support this channel/podcast with Ethereum (ETH): 0xd3F649C3403a4789466c246F32430036DADf6c62 Blockchain backup on Lbry https://odysee.com/@paulvanderklay https://www.patreon.com/paulvanderklay Paul's Church Content at Living Stones Channel https://www.youtube.com/channel/UCh7bdktIALZ9Nq41oVCvW-A To support Paul's work by supporting his church give here. https://tithe.ly/give?c=2160640

Dr. Peterson's extensive catalog is available now on DailyWire+: https://utm.io/ueSXhDr Jordan B Peterson and Dr. Robin Carhart-Harris delve into the world of psychedelic research, their utility in therapy, and the impact they can have on neuroticism. They also explore broader aspects of psychopathology, brain imaging, optimized play, and the way trauma can warp our perspectives of the world. Robin is the Ralph Metzner Distinguished Professor in Neurology and Psychiatry and Director of Neuroscape's Psychedelics Division at the University of California, San Francisco. He moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol. Robin has designed human brain imaging studies with LSD, psilocybin, MDMA and DMT, and several clinical trials of psilocybin therapy for severe mental illnesses. Robin founded the Centre for Psychedelic Research at Imperial College London in April 2019, was ranked among the top 31 medical scientists in 2020, and in 2021, was named in TIME magazine's ‘100 Next' – a list of 100 rising stars shaping the future. His research is creating system-level change in mental health care.  - Sponsors - Express VPN: Get 3 Months FREE of ExpressVPN: https://expressvpn.com/jordan Birch Gold: Text "JORDAN" to 989898 for a FREE Goldback with every $5000 purchase, when you convert an existing IRA or 401k into a precious metals IRA with Birch Gold by December 22nd. Black Rifle Coffee: Get 10% off your first order or Coffee Club subscription with code JORDAN: https://www.blackriflecoffee.com/ Exodus 90: Is it time for your Exodus? Find resources to prepare at https://exodus90.com/jordan.   - Links -  For Dr. Carhart-Harris: Twitter: https://twitter.com/RCarhartHarris Website:  https://neuroscape.ucsf.edu/profile/robin-carhart-harris/   - Chapters - (0:00) Coming Up(1:00) Intro(2:50) Implicit learning(7:52) Tuned perceptions, warped vantage points(12:00) Rebirth, rapid new learning(16:00) Alcoholism, unlearning pain(20:22) Neuroticism, Freud, and the disconnect(24:00) Cascading depression(30:10) Functional depression(35:30) The source of psychopathology(46:48) The psychedelic experience(49:47) Genetic mutation, error correction(53:30) Micro and macro environments(56:33) The multitude within(58:39) Pageau, optimized play(1:04:00) When play is absent from the system(1:07:25) Depth of play, levels of engagement(1:09:55) Local minima(1:13:29) Psychedelics and antidepressants(1:17:40) Creative surging under influence(1:21:30) Every benefit has a cost(1:23:32) Terrance and Dennis McKenna, false positives(1:26:15) Paranoid Schizophrenia(1:29:26) The feeling of confidence vs. uncertainty(1:33:33) Exposure therapy, building up bravery(1:35:00) Brain imaging, mapping experience(1:38:40) Entropic brain principle(1:40:00) Between order and chaos, Marduk(1:44:16) Signatures of criticality, the Alpha Rhythm       // SUPPORT THIS CHANNEL //Newsletter: https://mailchi.mp/jordanbpeterson.co...Donations: https://jordanbpeterson.com/donate // COURSES //Discovering Personality: https://jordanbpeterson.com/personalitySelf Authoring Suite: https://selfauthoring.comUnderstand Myself (personality test): https://understandmyself.com // BOOKS //Beyond Order: 12 More Rules for Life: https://jordanbpeterson.com/Beyond-Order12 Rules for Life: An Antidote to Chaos: https://jordanbpeterson.com/12-rules-...Maps of Meaning: The Architecture of Belief: https://jordanbpeterson.com/maps-of-m... // LINKS //Website: https://jordanbpeterson.comEvents: https://jordanbpeterson.com/eventsBlog: https://jordanbpeterson.com/blogPodcast: https://jordanbpeterson.com/podcast // SOCIAL //Twitter: https://twitter.com/jordanbpetersonInstagram: https://instagram.com/jordan.b.petersonFacebook: https://facebook.com/drjordanpetersonTelegram: https://t.me/DrJordanPetersonAll socials: https://linktr.ee/drjordanbpeterson #JordanPeterson #JordanBPeterson #DrJordanPeterson #DrJordanBPeterson #DailyWirePlus #podcast

Dr. Suresh Muthukumaraswamy — LSD Microdosing, Classical Psychedelics vs. Ketamine, Science and Speed in New Zealand, Placebo Options, and The Infinite Possibilities of Studying Mind-Altering CompoundsDr. Suresh Muthukumaraswamy completed his PhD in Psychology at the University of Auckland in 2005 after which he joined the newly established Cardiff University Brain Research Imaging Centre as a postdoctoral fellow. While at Cardiff, he started research work with psychedelics in 2011 in collaboration with Professor David Nutt and Dr. Robin Carhart-Harris investigating the neuroimaging correlates of the psychedelic drugs psilocybin and LSD. In 2014, Suresh received a prestigious Rutherford Discovery Fellowship and returned to the University of Auckland where he works in the School of Pharmacy at the Faculty of Medical and Health Sciences and leads the Auckland Neuropsychopharmacology Research Group.Suresh's main research interests are in understanding how therapies alter brain function and behavior and in testing methodologies to measure these changes in both healthy individuals and patient groups — particularly in depressed patients.At the University of Auckland, he has conducted clinical trials in depressed patients involving ketamine, scopolamine, and transcranial magnetic stimulation. He has received several Health Research Council of New Zealand research grants to support this work, including a grant to investigate the effects of microdoses of LSD on brain and cognitive function. Suresh has published 117 papers, with his work receiving 8000+ citations.This special episode of the podcast is a live recording from an event hosted by the Edmund Hillary Fellowship (EHF). EHF began in 2016 as a pilot immigration program and has matured into a fellowship of more than 500 technologists, creatives, investors, entrepreneurs, educators, and systems designers, committed to New Zealand as a base camp for global impact. From more than 50 different nationalities, including New Zealand, fellows span a range of high-value sectors: media, education, cleantech, venture capital, and mental health initiatives/research just to name a few.EHF and its fellows aim to make a meaningful impact in New Zealand/Aotearoa with projects that often have global applications.Please enjoy!*For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsorsSign up for Tim's email newsletter (5-Bullet Friday) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Discover Tim's books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissYouTube: youtube.com/timferrissFacebook: facebook.com/timferriss LinkedIn: linkedin.com/in/timferrissPast guests on The Tim Ferriss Show include Jerry Seinfeld, Hugh Jackman, Dr. Jane Goodall, LeBron James, Kevin Hart, Doris Kearns Goodwin, Jamie Foxx, Matthew McConaughey, Esther Perel, Elizabeth Gilbert, Terry Crews, Sia, Yuval Noah Harari, Malcolm Gladwell, Madeleine Albright, Cheryl Strayed, Jim Collins, Mary Karr, Maria Popova, Sam Harris, Michael Phelps, Bob Iger, Edward Norton, Arnold Schwarzenegger, Neil Strauss, Ken Burns, Maria Sharapova, Marc Andreessen, Neil Gaiman, Neil de Grasse Tyson, Jocko Willink, Daniel Ek, Kelly Slater, Dr. Peter Attia, Seth Godin, Howard Marks, Dr. Brené Brown, Eric Schmidt, Michael Lewis, Joe Gebbia, Michael Pollan, Dr. Jordan Peterson, Vince Vaughn, Brian Koppelman, Ramit Sethi, Dax Shepard, Tony Robbins, Jim Dethmer, Dan Harris, Ray Dalio, Naval Ravikant, Vitalik Buterin, Elizabeth Lesser, Amanda Palmer, Katie Haun, Sir Richard Branson, Chuck Palahniuk, Arianna Huffington, Reid Hoffman, Bill Burr, Whitney Cummings, Rick Rubin, Dr. Vivek Murthy, Darren Aronofsky, and many more.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

(Psychedelics Series) Del Jolly is a plant medicine advocate. What started as a stigma turned into a life's work.  After visiting The Realm of Caring, a cannabis non-profit helping families support their epileptic children with cannabis, Jolly quickly became an advocate. He worked for Charlotte's Web CBD for 3.5 years and was the outreach director for Decrim Denver, the historic psilocybin initiative that passed in Colorado on May 7th, 2019.  As psilocybin became more mainstream Jolly knew strong data would support those who were new to it and started Unlimited Sciences. U.S. has been working with Johns Hopkins to create the largest real-world data set on how people are using psilocybin. U.S. has evolved to launch other community-led psychedelic research and they are currently raising for a mostly female refugee, ayahuasca study including Dr. Robin Carhart Harris. Jolly recently launched Umbo, a functional mushroom company, and continues to advocate for plant medicine in Colorado. https://unlimitedsciences.org/Study: Ayahuasca for Immigrants and Refugeeshttps://www.gofundme.com/f/ayahuasca-study#BenStewart #DelJolly #PlantMedicine #Psychedelics #SolutionsBen Stewart Podcast strives to offer awareness and solutions to a rapidly evolving world, while building community… Produced live, Thursdays at 5:00 PM EST. Cohost/Producer: IG @Gordon_CummingsNow Multicast Streaming Live on Twitch! (Twitch Channel: https://www.twitch.tv/benjosephstewart)Join Our Kickass Discord Community!  https://discord.gg/7QadgxEK4zAccess Exclusive Content!https://www.benjosephstewart.com/plans-pricingCheck Out Latest Documentaries -   “Awake In The Darkness” - https://www.aubreymarcus.com/"DMT QUEST" - https://www.youtube.com/watch?v=My95s6ZryPgVisit https://www.BenJosephStewart.com/ to get more involved.Gaia Shows "Psychedelica" & "Limitless" with Free Trial.  https://www.gaia.com/invite/join?rfd=AGvFiE&utm_source=iafLike & Follow, Much Love -Facebook: https://www.facebook.com/BenJosephStewartMinds: https://www.minds.com/BenJosephStewart/Instagram: https://www.instagram.com/BenJosephStewart/Rumble: https://rumble.com/c/c-1044023Twitter: https://twitter.com/BenJosephStewBitChute: https://www.bitchute.com/channel/aanpGqOQt8ZX/TikTok: https://www.tiktok.com/@benstewartofficialOdysse: https://odysee.com/@BenStewart:6Twitch: https://www.twitch.tv/benjosephstewart

“Trauma is much more than a story about something that happened long ago,” writes Dr. Bessel van der Kolk. “The emotions and physical sensations that were imprinted during the trauma are experienced not as memories but as disruptive physical reactions in the present.”Van der Kolk, a psychiatrist by training, has been a pioneer in trauma research for decades now and leads the Trauma Research Foundation. His 2014 book “The Body Keeps the Score,” quickly became a touchstone on the topic. And although the book was first released over seven years ago, it now sits at No. 1 on the New York Times best-seller list, a testament to the state of our national psyche.The core argument of the book is that traumatic experiences — everything from sexual assault and incest to emotional and physical abuse — become embedded in the older, more primal parts of our brain that don't have access to conscious awareness. And that means two things simultaneously. First, that trauma lodges in the body. We carry a physical imprint of our psychic wounds. The body keeps the score. But — and I found this more revelatory — the mind hides the score. It obscures the memories, or convinces us our victimization was our fault, or covers the event in shame so we don't discuss it.There's a lot in this conversation. We discuss the lived experience of trauma, the relationship between the mind and the body, the differences between our “experiencing” and “autobiographical” selves, why van der Kolk believes human language is both a “miracle” and a “tyranny,” unconventional treatments for trauma from E.M.D.R. and yoga to psychedelics and theater, how societies can manage collective trauma like 9/11 and Covid-19, the shortcomings of America's “post-alcoholic” approach to dealing with psychic suffering, how to navigate the often complex relationships with the traumatized people we know and love, and much more.Mentioned: “The Adverse Childhood Experiences (ACE) Study” by Vince Felitti et al.Study on efficacy of EMDR“REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics” by Robin Carhart-Harris et al. Book Recommendations:The Apology by V Love in Goon Park by Deborah BlumThe Narrow Road to the Deep North by Richard Flanagan You can find transcripts (posted midday) and more episodes of "The Ezra Klein Show" at nytimes.com/ezra-klein-podcast, and you can find Ezra on Twitter @ezraklein.Thoughts? Guest suggestions? Email us at ezrakleinshow@nytimes.com.“The Ezra Klein Show” is produced by Annie Galvin, Jeff Geld and Rogé Karma; fact-checking by Michelle Harris; original music by Isaac Jones; mixing and engineering by Jeff Geld, audience strategy by Shannon Busta. Special thanks to Kristin Lin and Kristina Samulewski

LSD, designer shoes, and one of the pettiest feuds we have ever heard of. Join us this week as we talk epiphanies and enemies. Artwork: Jovana StekovicLogo:  nydaaaMusic: Home Base Groove by Kevin MacLeod   Karen's Sources:Beach Combing, “Beachcombing's Bizarre History Blog,” Beachcombing's Bizarre History Blog (April 2016)“Biography.com,” “Constantine I,” Biography.com (A&E Networks Television, May 2021)“Clueless,” Clueless. “Dictionary.com,” “Epiphany definition & meaning,” Dictionary.com (Dictionary.com). Editors of Encylcopedia Britannica, “Encyclopædia Britannica,” Encyclopædia Britannica (Encyclopædia Britannica, inc.). Elise Ballard, “Psychology Today,” Psychology Today (April 2011). Georgia Petridou, “Divine epiphany in greek literature and culture,” in Divine epiphany in greek literature and culture (Oxford: Oxford University Press, 2015). Herodotus and A.D. Godley, “Perseus,” Perseus (Tufts University). History Today | Published in History Today Volume 69 Issue 3 March 2019, “History Today,” History Today. “IMDb,” “When Harry Met Sally...,” IMDb (IMDb.com). Kit Kittelstad, “Your Dictionary,” Your Dictionary. “Mindbloom wordmark in dark blue,” “Mindbloom: Psychedelic Medicine is here,” Mindbloom wordmark in dark blue. Moises Velasquez-Manoff, “Nautilus,” Nautilus (March 2019). Myles Hudson, “Encyclopædia Britannica,” Encyclopædia Britannica (Encyclopædia Britannica, inc.). Olivia B. Waxman, “Time,” Time (Time, December 2020). Robin Carhart-Harris, “The Guardian,” The Guardian (June 2020). “Wikipedia,” “Eureka effect,” Wikipedia (Wikimedia Foundation, December 2021). William Braxton Irvine, Aha!: The moments of insight that shape our World (New York: Oxford University Press, 2015). “Woodhead Publishing,” “What is an epiphany in literature?,” Woodhead Publishing (2019). Casey's Sources:https://en.wikipedia.org/wiki/Dassler_brothers_feudhttps://en.wikipedia.org/wiki/Jesse_OwensHome Base Groove by Kevin MacLeod is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/ Source:  http://incompetech.com/music/royalty-free/index.html?isrc=USUAN1100563 Artist:  http://incompetech.com/ 

Thanks to The Psychedelic Society (http://psychedelicsociety.org.uk) for this excerpt from a  conversation between Rupert and Robin Carhart-Harris, with Stephen Reid hosting. Recorded on the 26th of June, 2019 at EartH, Hackney, London, UK.The full talk: https://youtu.be/l4HuFHWPc6k

What if a therapist could peer inside the black box of a patient's psychedelic experience? Adam Gazzaley and his Neuroscape team at UCSF are using multimodal biosensing research to make that dream a reality. On the show, Adam explains the concept of experiential medicine and how the brain modifies itself in response to different experiences. He shares his previous work creating a video game that is also a class two medical device for ADHD. He relates his long inquiry with shamans and therapists to understand how to design set and setting research studies. We explore the future of psychedelic therapy with a data-rich AI assistant and the potential concerns therapists might have about being replaced by innovative technology. Finally, Adam shares a powerful message to psychedelic healers and those who aspire to be. Adam Gazzaley is an American neuroscientist, author, photographer, entrepreneur and inventor. He is the founder and executive director of Neuroscape and the David Dolby Distinguished Professor of Neurology, Physiology, and Psychiatry at University of California, San Francisco. The new Neuroscape Psychedelics Division will be lead by Robin Carhart-Harris is dedicated to advancing the field of psychedelic science and medicine through multi-level research covering basic to translational to clinical science. Links Adam Gazzaley Neuroscape at UCSF Neuroracer in Nature “The Cognition Crisis” Timestamps :06 - How the brain modifies itself in response to experience :12 - How Adam got a video game approved as a class two medical device by the FDA :21 - Why Adam is studying the context (set and setting) of psychedelics :29 - Lessons from therapists and shamans that inform Adam's research :36 - Studying the impact of community, nature, and an ongoing healing journey. :47 - The future experience of a therapist using multimodal biosensing tools :53 - Could an AI associate displace the need for a therapist? 1:00 - Adam speaks to psychedelic therapists

Manesh is a PhD candidate in Neuroscience at McGill University and has been lead or co-author on over a dozen scientific publications and book chapters on topics including psychedelics, meditation, daydreaming, and the default-mode network.His PhD dissertation focuses on the default-mode network and he is also conducting research on the brain mechanisms underlying LSD, psilocybin, and DMT in collaboration with Dr. Robin Carhart-Harris and others from the Imperial College London Center for Psychedelic Research.In his free time, he also runs a YouTube channel - called The Psychedelic Scientist - where he discusses the latest findings in psychedelic science in an easy to understand, but non-superficial, form.In this episode, Beth and Manesh Girn speak about ...The similarities between the effects of psilocybin, LSD and DMTHow DMT temporarily overwhelms our brain's usual way of perceiving realityThe possibility that psychedelics may be able to heal us on an epigenetic levelThe utility of psychedelics across a variety of mental health challengesHow psychedelics can enhance the lives of healthy peopleHow psychedelics affect thinking, emotion, creativity, memory, attention and behaviorPsychedelics as a part of a holistic program of personal developmentThe challenge of integrating powerful insights from psychedelic experiencesPsychedelics and the default mode networkFollow Manesh!https://www.youtube.com/c/ThePsychedelicScientisthttps://www.instagram.com/thepsychedelicscientist/https://twitter.com/MGirnNeuro

Named one of Time Magazine's most influential people of 2021, Robin Carhart-Harris conducts some of the most impactful psychedelic research in the world. On the podcast, we review Robin's early research with MDMA and his involvement with the first fMRI and MEG studies of LSD. We talk about his 2016 study of psilocybin's efficacy with treatment-resistant depression and his most recent head-to-head comparison of the psychedelic with the SSRI Escitalopram (Lexapro). The outcome of that study calling into question a generation of psychiatric scales. As the former Head of the Centre for Psychedelic Research at Imperial College London, Dr. Robin Carhart-Harris is now moving to the Neuroscape Psychedelic Division at UCSF. For 15 years, his research has focused on how drugs such as LSD, psilocybin, DMT and MDMA work in the brain, and how they may be useful in treating disorders such as depression.‍ Robin is also an advisor to Maya, the measurement-based care platform that makes this show possible. Links Robin Carhart-Harris Time Magazine Adam Gazzaley Neuroscape at UCSF Timestamps :06 - Robin's early career from a masters in psychoanalysis to early experiments with MDMA :12 - fMRI and MEG studies of psychedelics :16 - Robin's first study of treatment-resistant depression in 2016 :30 - The first ever study of psychedelics head to head with an antidepressant :40 - Robin's future research :45 - Robin speaks to psychedelic therapists

Episode 10 features Lars Wilde, co-founder and Chief Business Officer of Compass Pathways, a mental health company with an initial focus on psilocybin therapy for Treatment-Resistant Depression.In this episode, we discuss:Lars' experience overcoming Treatment-Resistant Depression with psilocybinThe nuances of clinical trials and psilocybin dosing protocolsCompass Pathways' Intellectual Property strategyWhat additional indications and therapies Compass Pathways is interested inLinks to topics discussed in this episode:Compass Pathways, Lars WildeCOMP360SSRI, SNRIChristian Angermayer, Robin Carhart-Harris, Michael PollanVivaneoQuercis PharmaTRD (Therapy-Resistant Depression)Compass Phase 2B TrialJazz PharmaceuticalsCompass Pathways 2 US patentsOregon Psilocybin Therapy Measure 109Read the transcript here.Watch episode 10 on YouTube.Created by Greg Kubin and Matias SerebrinskyHosts: Matias Serebrinsky and Greg KubinProduced by Jonathan Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: River Meditation by Jason Shaw and Thea by Muted Circus

Robin Heads the Psychedelic Research Group within the Centre for Psychiatry at Imperial College London, where he has designed several functional brain imaging studies with psilocybin, LSD, MDMA  and DMT, plus a clinical trial of psilocybin for treatment resistant depression. He has over 50 published papers in peer-reviewed scientific journals; two of which were ranked in the top 100 most impactful academic articles of 2016. Robin's research has featured in major national and international media and he has given a popular TEDx talk.Does MDMA impact sleep?What does the brain look like under the influence of LSD?How do psychedelics change the quality of brain activity? Can psilocybin be used to treat depression? Psilocybin vs Escitalopram for Major Depressive Disorder  Stanislav Grof LSD PsychotherapyRobin's first paper – Waves of the Unconscious Amanda FeildingRobin's PhD Drugs live – Channel 4Psilocybin LSD MDMADMTPsychedelic resting states The entropic brainHomological scaffolds of brain functional networksThe Stoned Ape theory DMT Neural Correlates of the DMT experience Psilocybin for Treatment-Resistant Depression Serotonin and brain function: a tale of two receptors ★ Support this podcast ★

This week's episode features Dr Gabor Maté, a Hungarian-Canadian physician who's main interests include childhood development and trauma, and their impact on lifelong physical and mental health.  Professor Nutt and Dr Maté talk about the inseparable nature of our body and mind. How do they affect each other? How can psychedelics offer therapeutic potential to both mental and physical conditions?  Dr Gabor Maté was born in Hungary and emigrated to Canada as a young child. Following years of clinical practice, now retired, he travels around the world to speak about how life experiences shape our physical and mental health. In his books including the most recent “In the Realm of Hungry Ghosts: Close Encounters with Addiction” he explores the relationship between “early adversity” i.e. stress, childhood neglect or abuse and susceptibility to addictions, autoimmune diseases, cancer and many others. He is also widely recognised for his perspectives on attention deficit hyperactivity disorder.  Additionally, after being a part of an Ayahuasca retreat program Dr Gabor Maté advocates the therapeutic potential of this and other psychedelic substances in the treatment of a variety of mental and physical conditions. Gabor Mate's website In the Realm of Hungry Ghost The six realms of Buddhist cosmology Vancouver harm reduction program Ayahuasca Psilocybin Psilocybin and depression: Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms by Robin Carhart-Harris et al., 2017 Ayahuasca retreat with Dr. Gabor Maté and Richard Condon Scleroderma patient article:Ayahuasca Let Me Walk Again United Nation's Convention on Psychotropic Substances, 1971 When the Body Says No: The Cost of Hidden Stress Stress and the risk of multiple sclerosis Childhood Trauma in Multiple Sclerosis Psychedelics for psychological and existential distress in palliative and cancer care Become a Drug Science Community member ★ Support this podcast ★